Cell and Gene Outsourcing

31. Biopharmaceuticals Development And Manufacturing: Wide-Ranging Expertise And Vertically Integrated Service 11/17/2021

    The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art cGMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing.

32. Accelerate Development And De-Risk Gene Therapy Manufacturing 10/20/2023

    Join viral vector process and analytical development experts as they showcase strategies for developing robust processes and analytics for efficient and de-risked manufacturing.

33. Navigating The Complex Landscape Of Lentiviral Vector Quality Control 6/26/2025

    Explore the latest in lentiviral vector release testing, which covers biosafety, regulatory insights, and QC strategies to ensure patient safety and accelerate your path to clinic.

34. Accelerate Your AAV Journey To IND And Beyond 6/26/2025

    Explore essential QC strategies in AAV gene therapy and learn how to address rcAAV detection, viral clearance per ICH Q5A, and impurity profiling using NGS to meet evolving regulatory demands.

35. Quality Agreements: Defining Governance In CDMO Partnerships 5/15/2024

    Quality agreements serve a critical role within a CDMO-Sponsor partnership. Review the importance of aligning objectives, quality standards, and compliance frameworks to establish a robust foundation.

36. Optimizing Monoclonal Antibody Manufacturing For Commercial Success

    Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.

37. Combining Expertise With Best-In-Class Technology 10/20/2021

    Members of the MilliporeSigma leadership team reflect on the longstanding experience of our BioReliance® viral vector manufacturing facilities. Our legacy experience, alongside our brand new facility and latest industry innovations, ensure we are a preferred partner to pioneer the path to cures.

38. Characterizing AAV Encapsidated Nucleic Acid Sequences Using NGS 8/11/2023

    Here, we discuss the characterization of several representative AAV molecules using next-generation sequencing (NGS), including the sequencing process, bioinformatic analysis, and representative results.

39. A Faster, More Sensitive Approach To Virus Detection 2/13/2026

    Discover a faster, more sensitive approach to rodent virus detection that offers a targeted NGS workflow to help uncover contaminants traditional assays may miss.

40. Optimizing Viability And Standardization For Clinical Excellence 10/2/2024

    Explore how IntegriCell™ delivers high-quality, manufacture-ready cryopreserved leukopaks, vital for consistent and reliable cell therapy production.